Tharick A. Pascoal, Sulantha Mathotaarachchi, Monica Shin, Andrea L

Slides:



Advertisements
Similar presentations
2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.
Advertisements

Date of download: 7/8/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Intranasal Insulin Therapy for Alzheimer Disease and.
Date of download: 7/8/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Plasma Clusterin Concentration With.
Update of China-ADNI Kuncheng Li, MD. PhD.
Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment  Lies Clerx, Ineke A. van.
Value of cerebrospinal fluid visinin-like protein-1 (VILIP-1) for prediction of mild cognitive impairment progression to Alzheimer's disease  Mirjana Babić.
Volume 3, Issue 4, Pages (November 2017)
Volume 3, Issue 1, Pages (January 2017)
Rosa Maria Moresco University of Milan Bicocca
Manuela Tondelli, Gordon K. Wilcock, Paolo Nichelli, Celeste A
Arg-ADNI Patients’ Flowchart Patients Invited to ADNI Nº= 73
Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)
Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease  Azadeh Karami, Helga Eyjolfsdottir, Swetha.
The differential diagnosis of amnestic mild cognitive impairment and Alzheimer's disease dementia by hippocampal volume measurement with MR in a chinese.
Preventive Effect of Rifampicin on Alzheimer Disease Needs at Least 450 mg Daily for 1 Year: An FDG-PET Follow-Up Study - DOI: / Fig. 1.
Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints  Argonde C. van Harten, Pieter Jelle Visser,
Detecting functional decline from normal aging to dementia: Development and validation of a short version of the Amsterdam IADL Questionnaire  Roos J.
Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Alzheimer's disease biomarker-based clusters predict amyloid accumulation and cognitive decline in a preclinical cohort: Findings from the wisconsin registry.
DATA-DRIVEN TAU-PET COVARIANCE NETWORKS ENHANCE PREDICTION OF RETROSPECTIVE COGNITIVE CHANGE IN ALZHEIMER’S DISEASE  Jacob W. Vogel, Niklas Mattsson,
A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission.
Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment  Sanna-Kaisa Herukka,
Colin Groot, Chris W. J. van der Weijden, Wiesje M
Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 2, Issue 1, Pages (January 2016)
Volume 3, Issue 1, Pages (January 2017)
Ben Sherwood, Andrew Xiao-Hua Zhou, Sandra Weintraub, Lan Wang 
Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin  Eva Carro, Fernando Bartolomé, Félix Bermejo-Pareja,
Imaging AD Progression Amyloid Imaging Agents.
How to Characterize the Function of a Brain Region
Reisa Sperling, Elizabeth Mormino, Keith Johnson  Neuron 
Blood-Brain Barrier Breakdown in the Aging Human Hippocampus
Fusion of deep learning models of MRI scans, Mini–Mental State Examination, and logical memory test enhances diagnosis of mild cognitive impairment  Shangran.
Update of China-ADNI Kuncheng Li, MD. PhD.
Michael Ewers, Reisa A. Sperling, William E. Klunk, Michael W
Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)
Advances in the War on Alzheimer's
Biomarker Modeling of Alzheimer’s Disease
Figure 1 3D heat maps generated by GBM
Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups.
Figure 2 Comparison between noncarriers (−) and carriers (+) of the minor allele of rs (CYP2C19)‏ Comparison between noncarriers (−) and carriers.
A nonhuman primate model of early Alzheimer's disease pathologic change: Implications for disease pathogenesis  Caitlin S. Latimer, Carol A. Shively,
Clifford R. Jack, Heather J. Wiste, Stephen D. Weigand, Terry M
Figure 1 [18F]florbetapir standardized uptake value ratio analytical method [18F]florbetapir standardized uptake value ratio analytical method Flowchart.
Volume 24, Issue 1, Pages (July 2018)
Positron emission tomography study of regional cerebral blood flow and flow– metabolism coupling during general anaesthesia with xenon in humans†   S.
[18F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: Specific detection of advanced phases of amyloid-β.
Longitudinal uncoupling of cerebral perfusion, glucose metabolism, and tau deposition in Alzheimer's disease  Antoine Leuzy, Elena Rodriguez-Vieitez,
The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability.
Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective  Matthew Baumgart, Heather M. Snyder,
Effects of APOE-ε4 allele load on brain morphology in a cohort of middle-aged healthy individuals with enriched genetic risk for Alzheimer's disease 
Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study  Osama Sabri, Marwan N. Sabbagh, John Seibyl, Henryk Barthel,
A biomarker signal: Context-dependent hippocampal fMRI connectivity analysis of clinical trial measures in Alzheimer's disease  Donald McLaren, Reisa.
Sulantha S. Mathotaarachchi, Tharick A
Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Massimo S. Fiandaca, Mark E. Mapstone, Amrita K. Cheema, Howard J
Neuropathologic, genetic, and longitudinal cognitive profiles in primary age-related tauopathy (PART) and Alzheimer's disease  W. Robert Bell, Yang An,
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients  Eric R. Siemers, Karen L. Sundell, Christopher Carlson, Michael Case,
Cerebral hypoperfusion is not associated with an increase in amyloid β pathology in middle-aged or elderly people  Oskar Hansson, Sebastian Palmqvist,
Brain amyloid deposition and metabolism in early and late mild cognitive impairment  Jared Rowley, Liyong Wu, Sara Mohades, Marina Dauar, Antoine Leuzy,
Tharick A. Pascoal, Sulantha S
Fig. 1. AD biomarker levels in the cerebrospinal fluid of iNPH, AD, and CN subjects. Box plots of Aβ42 (A), Aβ40 (B), Aβ42/Aβ40 ratio (C), t-tau (D),
Fig. 2. Correlation between Aβ42 and Aβ40 levels in iNPH, AD, and CN subjects. The scatter plot shows the correlation between Aβ42 and Aβ40 levels. Representative.
Suzanne E. Schindler, Julia D. Gray, Brian A
A nonhuman primate model of early Alzheimer's disease pathologic change: Implications for disease pathogenesis  Caitlin S. Latimer, Carol A. Shively,
BRAIN AMYLOIDOSIS AND COGNITIVE DECLINE IN MCI: 12-MONTH FOLLOW-UP
Detecting and Diagnosing Alzheimer’s Disease
Figure 1 NMF in ADD patients and classification of prodromal Alzheimer’s disease participants. Grey matter ... Figure 1 NMF in ADD patients and classification.
CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER.
Susan D. Rountree, Alireza Atri, Oscar L. Lopez, Rachelle S. Doody 
Presentation transcript:

Synergistic interaction between amyloid and tau predicts the progression to dementia  Tharick A. Pascoal, Sulantha Mathotaarachchi, Monica Shin, Andrea L. Benedet, Sara Mohades, Seqian Wang, Tom Beaudry, Min Su Kang, Jean-Paul Soucy, Aurelie Labbe, Serge Gauthier, Pedro Rosa-Neto  Alzheimer's & Dementia: The Journal of the Alzheimer's Association  Volume 13, Issue 6, Pages 644-653 (June 2017) DOI: 10.1016/j.jalz.2016.11.005 Copyright © 2016 The Authors Terms and Conditions

Fig. 1 Schematic representation of the image analysis methods. Abbreviations: ADNI, Alzheimer's disease Neuroimaging Initiative; CSF, cerebrospinal fluid; GM, gray matter; MCI, mild cognitive impairment; MRI, magnetic resonance imaging; PET, positron emission tomography; SUVR, standardized uptake value ratio; WM, white matter. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 2017 13, 644-653DOI: (10.1016/j.jalz.2016.11.005) Copyright © 2016 The Authors Terms and Conditions

Fig. 2 The amnestic MCI Aβ+/p-tau+ individuals present the lowest baseline scores and the highest rate of decline in most neuropsychological functions. The values are presented in z-scores anchored in normative data of a cognitively normal population. In the box and whisker plots, the lower and upper boundaries show the 25th and 75th percentiles, respectively, whereas the horizontal line shows the median. The dots represent mild cognitive impairment (MCI) individuals less than the fifth or higher than the 95th percentile. Bonferroni-corrected P values for multiple comparisons indicate the values assessed with analyses of covariance adjusted for age, gender, years of education, APOE ε4 status, and baseline neuropsychological test score for longitudinal analysis. Post hoc multiple comparison analysis provided significant differences between biomarker groups for each neuropsychological test at *P < .05 and **P < .001. (A) At baseline, the Aβ+/p-tau+ group presented the lowest baseline scores in Mini-Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale–Cognitive Subscale (ADAS-Cog), logical memory immediate recall (LMI), and 30-minute delayed recall (LM30). The Aβ+/p-tau+ group showed worse performance in the Trail Making Test part B (TMT-B) than the Aβ−/p-tau− and Aβ−/p-tau+ groups. (B) The Aβ+/p-tau+ group presented the highest longitudinal impairment in all neuropsychological tests except TMT-A and MMSE. Aβ+/p-tau+ group showed higher decline in MMSE than Aβ−/p-tau− and Aβ−/p-tau+ groups. Notably, Aβ−/p-tau−, Aβ+/p-tau−, and Aβ−/p-tau+ groups did not differ from each other in any baseline or longitudinal cognitive performance. Abbreviations: Aβ, amyloid β; p-tau, phosphorylated tau. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 2017 13, 644-653DOI: (10.1016/j.jalz.2016.11.005) Copyright © 2016 The Authors Terms and Conditions

Fig. 3 Aβ+/p-tau+ individuals drove the rate of progression to dementia over 2 years in the amnestic MCI population. Abbreviations: Aβ, amyloid β; MCI, mild cognitive impairment; p-tau, phosphorylated tau. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 2017 13, 644-653DOI: (10.1016/j.jalz.2016.11.005) Copyright © 2016 The Authors Terms and Conditions

Fig. 4 Synergistic effect between [18F]florbetapir SUVR and CSF p-tau in temporal and inferior parietal cortices predicts progression to dementia. T-statistical parametric map, after correcting for multiple comparisons (random field theory at P < .001), overlaid in a structural magnetic resonance scan revealed that lateral and basal temporal and inferior parietal cortices were the brain regions where the synergism between [18F]florbetapir standardized uptake value ratio (SUVR) and cerebrospinal fluid (CSF) phosphorylated tau (p-tau) status was associated with an increased likelihood of progression to Alzheimer disease (AD) dementia over 2 years. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 2017 13, 644-653DOI: (10.1016/j.jalz.2016.11.005) Copyright © 2016 The Authors Terms and Conditions